Mercado mundial del síndrome de taquicardia ortostática postural: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado global del síndrome de taquicardia ortostática postural

Se espera que el mercado del síndrome de taquicardia ortostática postural crezca en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza el mercado para tener en cuenta un crecimiento a una CAGR del 6,10 % en el período de pronóstico mencionado anteriormente.

El síndrome de taquicardia ortostática postural (POTS) es un síndrome de intolerancia ortostática. Provoca un colapso del sistema nervioso, que se manifiesta como mareos, ansiedad, temblores e intolerancia ortostática, entre otros síntomas. El síndrome de taquicardia ortostática postural es un trastorno que afecta la circulación sanguínea. Pacientes de todos los géneros y edades pueden verse afectados por POTS. Por otro lado, las mujeres de entre 15 y 50 años son las más diagnosticadas. Antes de sus períodos menstruales, algunas mujeres experimentan un aumento de los síntomas de POTS. El POTS suele desarrollarse con un embarazo, una cirugía grave, un traumatismo o una infección viral. La diabetes mellitus crónica, la quimioterapia, la amiloidosis, el alcoholismo, la sarcoidosis, el síndrome de Sjögren, la intoxicación por metales pesados ​​y el lupus son las afecciones médicas que aumentarán el riesgo de síndrome de taquicardia ortostática postural.

The rise in the prevalence of postural orthostatic tachycardia syndrome will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of postural orthostatic tachycardia syndrome market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness and growing government funding are the factors that will expand the postural orthostatic tachycardia syndrome market. Other factors such as increase in the demand for effective therapies, growing incidences of amyloidosis, diabetes, sarcoidosis, and alcoholism and rising geriatric population will positively impact the postural orthostatic tachycardia syndrome market’s growth rate. Additionally, high disposable income and changing lifestyle will result in the expansion of postural orthostatic tachycardia syndrome market.

Moreover, the rise in the research and development activities and launch of effective therapies will provide beneficial opportunities for the postural orthostatic tachycardia syndrome market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate postural orthostatic tachycardia syndrome market in future.

However, high cost associated with the symptomatic treatment and lack of infrastructure in low-income countries will impede the growth rate of postural orthostatic tachycardia syndrome market. Additionally, the lack of cure for POTS will hinder the postural orthostatic tachycardia syndrome market growth. Less awareness will further challenge the market in the forecast period mentioned above.

This postural orthostatic tachycardia syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Postural orthostatic tachycardia syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Postural Orthostatic Tachycardia Syndrome Market Scope and Market Size

The postural orthostatic tachycardia syndrome market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of type, the postural orthostatic tachycardia syndrome market is segmented into neuropathic, hypovolemic, and hyperadrenergic.
• On the basis of treatment, the postural orthostatic tachycardia syndrome market is segmented into medication, diet, exercise and others. The medication segment is further sub-segmented into fludrocortisone, beta blockers, midodrine, clonidine, pyridostigmine, benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), erythropoietin and octreotide.
• On the basis of diagnosis, the postural orthostatic tachycardia syndrome market is segmented into biopsy of skin nerves, autonomic breathing test, valsava maneuver, quantitative sudomotor axon reflex test (QSART), electrocardiogram (EKG), blood tests, urine tests and others.
• On the basis of symptoms, the postural orthostatic tachycardia syndrome market is segmented into heart palpitations, headache, Temperature deregulation, nausea, anxiety, high/low blood pressure, dizziness, chest pain, abdominal pain, blurred eyesight, insomnia, diarrhea and others.
• On the basis of dosage, the postural orthostatic tachycardia syndrome market is segmented into injection, tablets and others.
• On the basis of route of administration, the postural orthostatic tachycardia syndrome market is segmented into oral, intravenous and others.
• On the basis of end-users, the postural orthostatic tachycardia syndrome market is segmented into clinic, hospital and others.

The postural orthostatic tachycardia syndrome market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Postural Orthostatic Tachycardia Syndrome Market Country Level Analysis

The postural orthostatic tachycardia syndrome market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel.

The countries covered in the postural orthostatic tachycardia syndrome market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the postural orthostatic tachycardia syndrome market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Postural orthostatic tachycardia syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Postural Orthostatic Tachycardia Syndrome Market Share Analysis

Postural orthostatic tachycardia syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to postural orthostatic tachycardia syndrome market research.

Some of the major players operating in the postural orthostatic tachycardia syndrome market are Novartis AG, Accord Healthcare, Bayer AG, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Mylan N.V., Zydus Pharmaceuticals, Inc., Allergan, Endo International plc, Teva Pharmaceutical Industries Ltd., WOCKHARDT, AstraZeneca, Johnson & Johnson Private Limited, Aurobindo Pharma, Currax Pharmaceuticals LLC., Avet Pharmaceuticals Inc., Mallinckrodt, Mayne Pharma Group Limited, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, DAIICHI SANKYO COMPANY, LIMITED, Sanofi, Lannett and ANGITA, among others.

SKU-67776